论文部分内容阅读
抗CD3单克隆抗体激活的杀伤细胞(anti-CD3 monoclonal antibody activated killer cells,CD3AK细胞)是一种新型的抗肿瘤免疫效应细胞,研究表明,它具有诱导方法简单、扩增效率高、低白细胞介索2(IL-2)依赖性、杀瘤活性显著高于LAK细胞的特点。临床应用也显示了良好的疗效和安全性,CD3AK细胞与手术、放疗或化疗联合,能有效地提高肿瘤患者机体的细胞免疫功能,协助消灭残存于体内的
Anti-CD3 monoclonal antibody activated killer cells (CD3AK cells) are a novel type of anti-tumor immune effector cells. Studies have shown that it has a simple induction method, high amplification efficiency, and low leukocyte count. The IL-2 dependent and tumoricidal activity was significantly higher than that of LAK cells. The clinical application also shows good efficacy and safety. The combination of CD3AK cells with surgery, radiotherapy or chemotherapy can effectively improve the cellular immune function of cancer patients and help eliminate the residuals in the body.